Allogeneic Hematopoietic Progenitor Cell Therapy

Covers allogeneic hematopoietic progenitor cell therapies, including Omisirge (omidubicil) and RegenCyte (HPC Cord Blood), for use in umbilical cord blood or unrelated‑donor hematopoietic progenitor cell transplantation. Intended for patients ≥12 years with hematologic malignancy or inherited/acquired hematopoietic disorders planned for myeloablative conditioning (Omisirge considered medically necessary for non‑Medicare members when criteria are met) and is limited to a single post‑conditioning administration; not covered for patients <12 years, non‑myeloablative/reduced‑intensity conditioning, multiple administrations, other stem cell sources, or uses outside the specified transplant settings (Medicare rules may differ).

"Policy addresses allogeneic hematopoietic progenitor cell therapies, including Omisirge (omidubicil) and RegenCyte (HPC Cord Blood)."

Sign up to see full coverage criteria, indications, and limitations.